ATE358480T1 - Verwendung von antagonisten der zentralen kannabinoidrezeptoren zur regulierung von suchterscheinungen - Google Patents

Verwendung von antagonisten der zentralen kannabinoidrezeptoren zur regulierung von suchterscheinungen

Info

Publication number
ATE358480T1
ATE358480T1 AT98904238T AT98904238T ATE358480T1 AT E358480 T1 ATE358480 T1 AT E358480T1 AT 98904238 T AT98904238 T AT 98904238T AT 98904238 T AT98904238 T AT 98904238T AT E358480 T1 ATE358480 T1 AT E358480T1
Authority
AT
Austria
Prior art keywords
addiction
antagonists
regulate
cannabinoid receptors
central cannabinoid
Prior art date
Application number
AT98904238T
Other languages
English (en)
Inventor
Jeanne Maruani
Philippe Soubrie
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE358480T1 publication Critical patent/ATE358480T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
AT98904238T 1997-01-28 1998-01-28 Verwendung von antagonisten der zentralen kannabinoidrezeptoren zur regulierung von suchterscheinungen ATE358480T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9700870A FR2758723B1 (fr) 1997-01-28 1997-01-28 Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments

Publications (1)

Publication Number Publication Date
ATE358480T1 true ATE358480T1 (de) 2007-04-15

Family

ID=9503028

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98904238T ATE358480T1 (de) 1997-01-28 1998-01-28 Verwendung von antagonisten der zentralen kannabinoidrezeptoren zur regulierung von suchterscheinungen

Country Status (32)

Country Link
US (3) US6344474B1 (de)
EP (2) EP1795194A3 (de)
JP (1) JP3676383B2 (de)
AR (1) AR011776A1 (de)
AT (1) ATE358480T1 (de)
AU (1) AU6219398A (de)
BR (1) BR9806801A (de)
CA (1) CA2278661A1 (de)
DE (1) DE69837473T2 (de)
DK (1) DK0969835T3 (de)
DZ (1) DZ2405A1 (de)
EE (1) EE04630B1 (de)
ES (1) ES2285760T3 (de)
FR (1) FR2758723B1 (de)
GT (1) GT199800021A (de)
HK (1) HK1022829A1 (de)
HR (1) HRP980042A2 (de)
ID (1) ID22216A (de)
IS (1) IS5113A (de)
LV (1) LV12354B (de)
ME (1) MEP26508A (de)
MY (1) MY117251A (de)
NO (1) NO323696B1 (de)
PT (1) PT969835E (de)
RS (1) RS49830B (de)
SA (1) SA98181113B1 (de)
SK (1) SK99799A3 (de)
TR (1) TR199901721T2 (de)
TW (1) TW450808B (de)
UY (1) UY24847A1 (de)
WO (1) WO1998032441A1 (de)
ZA (1) ZA98691B (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
CA2398199A1 (en) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha Novel therapeutic agents that use a .beta.3 agonist
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
GB0010960D0 (en) * 2000-05-05 2000-06-28 Glaxo Group Ltd Assay
FR2809725B1 (fr) * 2000-06-06 2004-05-07 Sanofi Synthelabo Propanolaminotetralines, leur preparation et compositions pharmaceutiques en contenant
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US20050054730A1 (en) * 2001-03-27 2005-03-10 The Regents Of The University Of California Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
CN1523982A (zh) 2001-03-27 2004-08-25 ���������Ǵ�ѧ���»� 减少体脂和调节脂肪酸代谢的方法、化合物和组合物
WO2003007887A2 (en) * 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
NZ535349A (en) 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
NZ534757A (en) * 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
JP2005528366A (ja) * 2002-03-26 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体モジュレータとしてのスピロ環式アミド
US7271266B2 (en) * 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
CA2480856A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
US7667053B2 (en) * 2002-04-12 2010-02-23 Merck & Co., Inc. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
CA2483464C (en) 2002-05-17 2011-12-20 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
JP2006517194A (ja) 2002-06-06 2006-07-20 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 骨成長を調節するための方法、組成物および製造物
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
AU2003296895A1 (en) * 2002-08-20 2004-05-04 The Regents Of The University Of California Combination therapy for controlling appetites
EP1546115A4 (de) 2002-09-27 2010-08-04 Merck Sharp & Dohme Substituierte pyrimidine
US7765162B2 (en) * 2002-10-07 2010-07-27 Mastercard International Incorporated Method and system for conducting off-line and on-line pre-authorized payment transactions
MXPA05004115A (es) * 2002-10-18 2005-06-22 Pfizer Prod Inc Ligandos del receptor cannabionoide y usos de los mismos.
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
CA2510785C (en) * 2002-12-19 2013-04-09 Merck & Co., Inc. Substituted amides
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
JP4343948B2 (ja) 2003-04-29 2009-10-14 オレキシジェン・セラピューティクス・インコーポレーテッド 体重減少に影響を及ぼすための組成物
EP1622876A1 (de) * 2003-05-07 2006-02-08 Pfizer Products Inc. Cannabinoid rezeptorenliganden und ihre verwendung
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
WO2004113320A1 (en) * 2003-05-20 2004-12-29 The University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
EP1663215A1 (de) * 2003-09-02 2006-06-07 Solvay Pharmaceuticals GmbH Neue medizinische verwendung von selektiven cb1-rezeptorantagonisten
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
JP2007509066A (ja) * 2003-10-16 2007-04-12 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 体脂肪を減らし、食欲を抑制し、脂肪酸代謝を調節するための食物および他の組成物、化合物ならびに方法
FR2861301B1 (fr) * 2003-10-24 2008-07-11 Sanofi Synthelabo Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2861302A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2861300B1 (fr) * 2003-10-24 2008-07-11 Sanofi Synthelabo Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
RU2006117637A (ru) * 2003-10-24 2007-12-10 Зольвай Фармасьютиклз Гмбх (De) Комбинированное лечение ожирения с применением избирательных антагонистов cb1-рецептора и ингибиторов липаз
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
CA2543882A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
CN1875021A (zh) * 2003-11-04 2006-12-06 默克公司 取代的萘啶酮衍生物
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
JP2007517901A (ja) 2004-01-13 2007-07-05 デューク・ユニバーシティー 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
JP2007533661A (ja) * 2004-03-31 2007-11-22 ニューロジェン・コーポレーション 体重管理のための併用療法
WO2005107806A1 (en) * 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2005102304A1 (en) * 2004-04-23 2005-11-03 Northern Sydney And Central Coast Area Health Service Methods and compositions for the treatment of myocardial conditions
MXPA06012685A (es) * 2004-05-03 2007-01-16 Univ Duke Composiciones para afectar la perdida de peso.
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
KR20070041717A (ko) 2004-07-12 2007-04-19 카딜라 핼쓰캐어 리미티드 카나비노이드 수용체 조절자인 트리시클릭 피라졸 유도체들
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
KR20070083534A (ko) * 2004-08-03 2007-08-24 오렉시젠 세러퓨틱스 인크. 체중감량을 위한 부프로피온과 제2화합물의 조합
JP2008514718A (ja) * 2004-09-29 2008-05-08 シェーリング コーポレイション 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
WO2006045799A2 (en) * 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
JP4926069B2 (ja) 2004-11-01 2012-05-09 アミリン・ファーマシューティカルズ，インコーポレイテッド 肥満ならびに肥満関連疾患および障害の治療方法
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
KR20070089151A (ko) * 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
WO2006060192A2 (en) * 2004-11-30 2006-06-08 Bayer Pharmaceuticals Corporation Pyrazole derivatives
US8853205B2 (en) 2005-01-10 2014-10-07 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
AU2006203845A1 (en) * 2005-01-10 2006-07-13 Alexandros Makriyannis Novel heteropyrrole analogs acting on cannabiniod receptors
FR2882365B1 (fr) * 2005-02-21 2007-09-07 Sanofi Aventis Sa Derives de 2-(1,5-diphenyl-1h-pyrazol-3-yl)-1,3,4-oxadiazole leur preparation et leur application en therapeutique
WO2006087481A1 (fr) * 2005-02-21 2006-08-24 Sanofi-Aventis Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
GB0514739D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
CA2518579A1 (en) * 2005-08-05 2007-02-05 University Technologies International Inc. Method for appetite suppression
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
AR056560A1 (es) * 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
JPWO2007139062A1 (ja) * 2006-05-30 2009-10-08 杏林製薬株式会社 肥満治療剤並びに肥満の治療及び予防方法
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1886684A1 (de) * 2006-08-07 2008-02-13 Ratiopharm GmbH Rimonabant-haltiges Arzneimittel
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
JP2010509367A (ja) 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド 積層製剤
MX2009004871A (es) * 2006-11-09 2009-06-16 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
FR2914554B1 (fr) * 2007-04-05 2009-07-17 Germitec Soc Par Actions Simpl Procede de suivi de l'uitilisation d'un appareil medical.
PE20090142A1 (es) * 2007-04-11 2009-02-19 Merck & Co Inc Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
US8293786B2 (en) * 2007-07-30 2012-10-23 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
BRPI0722276A2 (pt) * 2007-11-14 2014-04-22 Amylin Pharmaceuticals Inc Métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
WO2009126691A1 (en) * 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US10053444B2 (en) 2009-02-19 2018-08-21 University Of Connecticut Cannabinergic nitrate esters and related analogs
ES2493916T3 (es) 2009-04-07 2014-09-12 Infinity Pharmaceuticals, Inc. Inhibidores de hidrolasa de amida de ácidos grasos
CA2757622A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8765735B2 (en) * 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) * 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8927551B2 (en) * 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2011067225A1 (en) 2009-12-01 2011-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions targeting cb1 receptor for controlling food intake
CA2785822C (en) 2010-01-11 2019-06-25 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
WO2011097233A1 (en) 2010-02-03 2011-08-11 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
JP6092870B2 (ja) 2011-08-19 2017-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア メタ置換ビフェニル末梢に限局されたｆａａｈ阻害剤
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
KR20150016405A (ko) 2012-06-06 2015-02-11 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
WO2015157313A1 (en) 2014-04-07 2015-10-15 The Regents Of The University Of California Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
CA3125847A1 (en) 2020-07-27 2022-01-27 Makscientific, Llc Process for making biologically active compounds and intermediates thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79323A (en) 1985-07-10 1990-03-19 Sanofi Sa Phenylethanolaminotetralines,their preparation and pharmaceutical compositions containing them
IE65511B1 (en) * 1989-12-29 1995-11-01 Sanofi Sa New phenylethanolaminomethyltetralins
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
EP0627407A1 (de) * 1993-05-28 1994-12-07 MIDY S.p.A. (7S)-7-(2R)-2(3-Chlorophenyl)-2-hydroxethylamino-5,6,7,8-Tetrahydronaphthalen-2-yloxy-Essigsäure, ihre pharmazeutisch akzeptablen Salze, mit Beta-3-adrenergischer agonistischer Aktivität und diese enthaltende pharmazeutische Zusammensetzung
US5578638A (en) * 1993-11-05 1996-11-26 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
EP0795327A1 (de) * 1996-03-13 1997-09-17 Pfizer Inc. Verwendung von Amlodipin zur Behandlung von Prophylaxe von kongestivem Herzversagen nichtischämischen Ursprungs

Also Published As

Publication number Publication date
UY24847A1 (es) 1998-04-21
NO993634L (no) 1999-09-27
FR2758723A1 (fr) 1998-07-31
MEP26508A (en) 2010-06-10
NO993634D0 (no) 1999-07-27
MY117251A (en) 2004-06-30
EE9900304A (et) 2000-02-15
SA98181113B1 (ar) 2006-06-25
TW450808B (en) 2001-08-21
IS5113A (is) 1999-07-12
RS49830B (sr) 2008-08-07
CA2278661A1 (en) 1998-07-30
EE04630B1 (et) 2006-06-15
JP3676383B2 (ja) 2005-07-27
TR199901721T2 (xx) 1999-10-21
EP0969835A1 (de) 2000-01-12
LV12354A (lv) 1999-10-20
NO323696B1 (no) 2007-06-25
US20050026986A1 (en) 2005-02-03
SK99799A3 (en) 2000-06-12
HRP980042A2 (en) 1998-10-31
ZA98691B (en) 1998-08-05
DE69837473D1 (de) 2007-05-16
AR011776A1 (es) 2000-09-13
JP2001501971A (ja) 2001-02-13
YU35099A (sh) 2002-08-12
AU6219398A (en) 1998-08-18
ES2285760T3 (es) 2007-11-16
GT199800021A (es) 1999-07-22
US6344474B1 (en) 2002-02-05
EP1795194A2 (de) 2007-06-13
EP1795194A3 (de) 2008-04-30
LV12354B (en) 2000-02-20
EP0969835B1 (de) 2007-04-04
ID22216A (id) 1999-09-16
BR9806801A (pt) 2000-05-16
PT969835E (pt) 2007-07-12
WO1998032441A1 (fr) 1998-07-30
US20020128302A1 (en) 2002-09-12
HK1022829A1 (en) 2000-08-25
DK0969835T3 (da) 2007-08-06
FR2758723B1 (fr) 1999-04-23
DE69837473T2 (de) 2007-12-13
DZ2405A1 (fr) 2003-01-04

Similar Documents

Publication Publication Date Title
ATE358480T1 (de) Verwendung von antagonisten der zentralen kannabinoidrezeptoren zur regulierung von suchterscheinungen
DE69816100D1 (de) Herstellung von membranrezeptoren mit extrazellulären baculovirus
DE60020145D1 (de) Verwendung von einem antagonist der zentralen kannabinoidrezeptoren zur herstellung von arzneimitteln
DE69837916D1 (de) Verwendung von glyphosat-resistente maislinien
DE69841307D1 (de) Verwendung von peroxiden zur bekämpfung der haarigen warzenerkrankung
DE19882126T1 (de) Hydrierung von Kohlenwasserstoffen
ATE239011T1 (de) Neuartige form von s-omeprazol
EE200000778A (et) 4-bensüülpiperidiinalküülsulfoksiidi heterotsüklid ja nende kasutamine NMDA retseptori alaliikide suhtes selektiivsete antagonistidena
PL330849A1 (en) Antagonists of il-8 receptors
DE19882125T1 (de) Direkte Abscheidung von Palladium
DE69821072D1 (de) Echtzeit bildgesteuerte Positionierung von Verankerungseinheiten
PT968194E (pt) Atropisomeros de 3-aril-4(3h)-quinazolinonas e sua utilizacao como antagonistas dos receptores ampa
DE69622279D1 (de) Elektroseismische technik zur bestimmung der eigenschaften von gestein um ein bohrloch
DE69822355D1 (de) Verwendung von einer verkapselten bioaktiven Zusammensetzung
DE69715827T2 (de) Verwendung von aloe extrakt enthaltenden zahnprothesehaftmitteln
ATE242198T1 (de) Modulatoren von exzitatorischen aminosäure rezeptoren
PT1131291E (pt) Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
DE69719191D1 (de) Tetrahydroisoquinoline derivate als modulatoren von dopamine d3 rezeptoren
DE977852T1 (de) Damilie von immunregulatoren mit der bezeichnung leukozyten immunglobulin-ähnliche rezeptoren (lir)
DE69628195D1 (de) Verwendung von xyloglucanendotransglycosylase
DE59502125D1 (de) Verwendung von lösungsmittelfesten textilbindern
DE69928437D1 (de) Verwendung von paraoxanase-1 (pon-1) zur reduzierung der atheroma-bildung und der hypercholesterolemie
DE69834262D1 (de) Neue pharnazeutische verwendung von c-c chemokin produktionsinhibitoren
DE69805450D1 (de) Verwendung von überzogenen Tierkohlezusammensetzungen
DE59811806D1 (de) Verwendung von ausgewählten phytostenolestern zur herstellung von hypocholesterinämischen mitteln

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0969835

Country of ref document: EP

REN Ceased due to non-payment of the annual fee